CYP3A activity and expression in nonalcoholic fatty liver disease
SJ Woolsey, SE Mansell, RB Kim, RG Tirona… - Drug Metabolism and …, 2015 - ASPET
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in the Western
world, given its association with obesity, type 2 diabetes, and dyslipidemia. Medications are …
world, given its association with obesity, type 2 diabetes, and dyslipidemia. Medications are …
Going mobile with diabetes support: a randomized study of a text message–based personalized behavioral intervention for type 2 diabetes self-care
K Capozza, S Woolsey, M Georgsson… - Diabetes …, 2015 - Am Diabetes Assoc
Objective. Patients with type 2 diabetes often fail to achieve self-management goals. This
study tested the impact on glycemic control of a two-way text messaging program that provided …
study tested the impact on glycemic control of a two-way text messaging program that provided …
Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease
…, WA Teft, BL Morse, YH Choi, S Woolsey… - Digestive diseases and …, 2015 - Springer
Background The gastrointestinal (GI) microbiome is recognized for potential clinical relevance
in inflammatory bowel disease (IBD). Data suggest that there is a disease-dependent loss …
in inflammatory bowel disease (IBD). Data suggest that there is a disease-dependent loss …
Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response
…, D Sugiyama, MK DeGorter, S Woolsey… - European heart …, 2012 - academic.oup.com
Aims It is thought that clopidogrel bioactivation and antiplatelet response are related to
cytochrome P450 2C19 (CYP2C19). However, a recent study challenged this notion by …
cytochrome P450 2C19 (CYP2C19). However, a recent study challenged this notion by …
Pharmacist-provided diabetes management and education via a telemonitoring program
…, L Lenert, M Petersen, S Woolsey… - Journal of the American …, 2015 - Elsevier
Objective To assess clinical outcomes (glycosylated hemoglobin [A1C], blood pressure, and
lipids) and other measurements (disease state knowledge, adherence, and self-efficacy) …
lipids) and other measurements (disease state knowledge, adherence, and self-efficacy) …
The Utah Remote Monitoring Project: improving health care one patient at a time
…, L Lenert, M Petersen, S Woolsey… - Diabetes Technology …, 2014 - liebertpub.com
Background: The expanding role of technology to augment diabetes care and management
highlights the need for clinicians to learn about these new tools. As these tools continue to …
highlights the need for clinicians to learn about these new tools. As these tools continue to …
Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P 450 3 A Activity and Single‐Time‐Point Oral Midazolam Microdose Phenotype …
SJ Woolsey, MD Beaton, YH Choi… - Basic & clinical …, 2016 - Wiley Online Library
Due to high basal interindividual variation in cytochrome P 450 3 A ( CYP 3 A ) activity and
susceptibility to drug interactions, there has been interest in the application of efficient probe …
susceptibility to drug interactions, there has been interest in the application of efficient probe …
A fibroblast growth factor 21–pregnane X receptor pathway downregulates hepatic CYP3A4 in nonalcoholic fatty liver disease
SJ Woolsey, MD Beaton, SE Mansell… - Molecular …, 2016 - ASPET
Nonalcoholic fatty liver disease (NAFLD) alters drug response. We previously reported that
NAFLD is associated with reduced in vivo CYP3A drug-metabolism activity and hepatic …
NAFLD is associated with reduced in vivo CYP3A drug-metabolism activity and hepatic …
Diagnosing hypertension in primary care clinics according to current guidelines
S Woolsey, B Brown, B Ralls… - The Journal of the …, 2017 - Am Board Family Med
Purpose: This descriptive study examines hypertension diagnostic practices in Utah primary
care clinics relative to the 2015 US Preventive Services Task Force (USPSTF) …
care clinics relative to the 2015 US Preventive Services Task Force (USPSTF) …
Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor
EF Choo, S Woolsey, K DeMent, J Ly, K Messick… - Drug Metabolism and …, 2015 - ASPET
Data from the clinical absolute bioavailability (F) study with cobimetinib suggested that F
was lower than predicted based on its low hepatic extraction and good absorption. The …
was lower than predicted based on its low hepatic extraction and good absorption. The …